Even if you withdraw your consent to research participation, 23andMe acknowledges that research already conducted using your deidentified data cannot be reversed or recalled from studies already underway or completed.
This analysis describes what 23andMe's agreement states, permits, or reserves. It does not constitute a legal determination about enforceability. Regulatory applicability and practical outcomes may vary by jurisdiction, enforcement context, and individual circumstances. Read our methodology
The clause establishes the operational mechanism for research data aggregation and clarifies that participation is not permanent or irrevocable, permitting users to withdraw from the research program prospectively.
Interpretive note: The adequacy of the deidentification standard applied and whether it satisfies GDPR anonymization requirements is not detailed in the document excerpt; this determination significantly affects the legal exposure under the right to erasure.
The updated privacy statement no longer explicitly directs users to a separate Medical Record Privacy Notice for telehealth services or explains that medical information collected through telehealth is governed by different privacy rules. Previously, the policy stated that users choosing telehealth services coordinated through 23andMe would find healthcare privacy protections described in a separate notice. That reference is now absent from the main privacy statement. Users seeking privacy information specific to telehealth services will need to determine independently whether a separate notice exists or contact 23andMe directly using the provided contact information.
View change record →The updated privacy statement no longer explicitly discloses a separate Medical Record Privacy Notice that previously described how medical information is used, disclosed, and maintained for telehealth services. Users who receive telehealth services coordinated through 23andMe may now lack clear notice of which privacy framework governs their medical records, since the reference to that parallel notice has been removed. The organizational scope change from '23andMe Research Institute' to '23andMe' narrows the explicitly named entities responsible for the policy, though operational impact depends on how these entities actually function.
View change record →Opting out of research stops future use of your data but does not undo contributions to studies already in progress or completed, meaning your genetic data may have permanently contributed to commercial drug development research without the ability to withdraw that contribution.
How other platforms handle this
If you are a California resident, you have the right to: Know what personal information is being collected about you; Know whether your personal information is sold or disclosed and to whom; Say no to the sale of personal information; Access your personal information; Request deletion of your person...
After your account is deleted, we keep data about interactions you've had on our service to prevent abuse, ban evaders and others in an effort to protect and ensure the safety and security of our service and our members.
Depending on where you live, you may have certain rights with respect to your personal information, such as the right to request access, correction, or deletion of your personal information, or to opt out of the sale or sharing of your personal information. If you are a California resident, you have...
Monitoring
23andMe has changed this document before.
Receive same-day alerts, structured change summaries, and monitoring for up to 25 platforms.
"If you choose to participate in research, your deidentified data will be pooled with data from other participants. You can opt out at any time.— Excerpt from 23andMe's 23andMe Privacy Statement
REGULATORY LANDSCAPE: The irreversibility of past research use creates direct tension with the right to erasure under GDPR Article 17, which does not contain a blanket exception for deidentified research data in all circumstances. The European Data Protection Board has issued guidance on the conditions under which research exemptions to the right to erasure apply, and the adequacy of deidentification as a basis for retaining research exemption status is subject to regulatory scrutiny. Under CCPA, deletion rights may also be implicated depending on whether deidentified data retains any linkability to the original subject. GOVERNANCE EXPOSURE: High. The assertion that past research use is irreversible is legally and regulatorily contested in key jurisdictions. Regulators in the EU have taken the position that truly anonymized data falls outside GDPR scope, but the adequacy of genetic data deidentification is specifically questioned given the re-identification risks inherent in genomic data. This provision may face challenge from EU data protection authorities. JURISDICTION FLAGS: EU/EEA users and UK users have the strongest grounds to challenge the irreversibility claim under GDPR and UK GDPR respectively. California users' CCPA deletion rights and the interaction with research use exemptions require careful legal analysis. Users in jurisdictions with strict bioethics frameworks may have additional protections beyond data protection law. CONTRACT AND VENDOR IMPLICATIONS: Research partner agreements should be reviewed to confirm whether they include provisions for data withdrawal or destruction upon user opt-out requests, and whether contractual commitments align with what is disclosed to users in this policy. Any discrepancy between contractual capabilities and policy representations creates legal exposure. COMPLIANCE CONSIDERATIONS: The policy's acknowledgment of irreversibility should be evaluated against GDPR's right to erasure and the principle that consent withdrawal must be as easy as giving consent. Legal teams should assess whether the deidentification standard applied to research data satisfies the GDPR standard for true anonymization, which would remove the data from GDPR scope, or whether it constitutes pseudonymization, which remains within scope and subject to deletion rights.
Full compliance analysis
Regulatory citations, enforcement risk, and due diligence action items.
Free: track 1 platform + weekly digest. Monitor: 25 platforms + same-day alerts. No credit card required.
Ad personalization controls removed. Contact scanning added. Advertiser data partnerships quietly dropped. A timeline of every change.
Compliance Governance Intelligence
Need to monitor specific governance provisions?
Compliance includes provision-level monitoring, governance timelines, regulatory mapping, and audit-ready analysis.
Built from archived source documents, structured governance mappings, and historical version tracking.
The clause establishes the operational mechanism for research data aggregation and clarifies that participation is not permanent or irrevocable, permitting users to withdraw from the research program prospectively.
Opting out of research stops future use of your data but does not undo contributions to studies already in progress or completed, meaning your genetic data may have permanently contributed to commercial drug development research without the ability to withdraw that contribution.
No. ConductAtlas is an independent monitoring service. We are not affiliated with, endorsed by, or sponsored by 23andMe.